SAN MATEO, Calif., Sept. 21, 2023 (World NEWSWIRE) — Bluejay Therapeutics, Inc. a non-public clinical phase biopharmaceutical firm concentrated on viral and liver disorders, currently declared the appointment of Christopher Holterhoff as Senior Vice President, Head of Company Enhancement. Mr. Holterhoff will direct Bluejay’s business enterprise and corporate enhancement purpose and will play a considerable position in Bluejay’s corporate method and strategic setting up functions. He will be a member of Bluejay’s Executive staff, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
“I am delighted to welcome Chris to the senior management staff at Bluejay”, stated Mrs. Chu. “Chris has an exceptional observe record in business enterprise & company growth with each general public and personal biotech and pharma providers. His business improvement encounter, as nicely as his strategic aptitude will engage in a vital part as we execute on our vision of developing a foremost biotechnology company centered on healing treatment options for severe viral and liver diseases.”
“Bluejay is really very well-positioned with a pipeline of initial-in-class or most effective-in-class remedy alternatives addressing serious and remarkably commonplace viral and liver health conditions in which there exists substantial unmet health care want. I am thrilled to be a part of the group at these kinds of a pivotal time in its improvement, and I look forward to operating with Bluejay’s outstanding staff and leveraging my practical experience in company advancement to progress the company’s promising pipeline toward acceptance for clients who are in dire need of new procedure options.”
Mr. Holterhoff has approximately two decades of numerous encounter encompassing business enterprise & company progress, corporate finance & tactic, and funds marketplaces.
Before signing up for Bluejay, he served as VP, Enterprise & Corporate enhancement at LEXEO Therapeutics, where he led all company development, strategic transactions and played